Job Description
The Officer Onco Solid Oral will be responsible for the development and management of solid oral dosage forms specifically for oncology products. This role requires a candidate with a strong background in pharmaceutical sciences and experience in the oncology field to ensure compliance with regulatory standards.
Responsibilities
- Develop and implement strategies for the management of solid oral oncology products.
- Conduct stability studies and manage documentation related to product development.
- Collaborate with cross-functional teams to ensure compliance with regulatory standards.
- Assist in the preparation of regulatory submissions and maintain product dossiers.
- Support clinical trials and provide necessary documentation and data analysis.
Skills and Qualifications
- Bachelor's or Master's degree in Pharmacy, Pharmaceutical Sciences, or a related field.
- 2-5 years of experience in oncology pharmaceuticals or solid oral dosage forms.
- Strong understanding of regulatory requirements for oncology products in India.
- Proficiency in data analysis and interpretation relevant to pharmaceutical development.
- Excellent communication and interpersonal skills for effective teamwork.
More Info
Key Skills
About Company
Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business.
Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK.
Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests 6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products.
Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies.
The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab.
Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.